Persistent expression of canine factor IX in hemophilia B canines.
about
An integrated 4249 marker FISH/RH map of the canine genomeIntrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in ratsExtrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome.Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.Gene therapy for haemophilia: the end of a 'royal pathology' in the third millennium?Gene therapy for haemophilia.Parvovirus-mediated gene transfer for the haemophilias.Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins.Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.Safety of adeno-associated virus gene therapy vectors: a current evaluation.Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).Preclinical and clinical gene therapy for haemophilia.Dog star rising: the canine genetic system.Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors.Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?Prediction of adeno-associated virus neutralizing antibody activity for clinical application.Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependentCytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors.Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.Gene Therapy for Hemophilia: Progress to Date.
P2860
Q24796208-93264CE7-29E0-4195-8AC7-7D3E6D7D1405Q25256466-61AA32BE-B129-41AE-9DE0-340A58EC5234Q33844362-2764852C-7CE6-48F7-A62C-B91963E2861AQ33870310-B81420D0-7B5B-4882-B80E-60ED70FE71FCQ34161415-FD4CEE95-3045-425B-AD43-C6A0657668D9Q34368127-395302F9-C4DF-413A-AFAE-B9606EE9EE0BQ34530130-716E7494-B83D-40E7-85C2-CCB768070851Q34609626-64AF366F-E10F-449A-8590-E196970D2A4CQ34777289-1DE94F2A-7A0D-4BC0-9E70-80F0B1E6EE97Q34985105-69D67447-17DB-4B52-AA5A-23195097C2FDQ35006603-77B11895-3FD0-46F7-ADB6-C0A8B62DB910Q35194547-AFE7588D-9291-4293-8D42-4D3F0324D5E1Q35876970-50F298F4-BD47-44EA-B299-AF87CBA7AB0FQ35904461-40E90EA1-453A-4437-81D2-83DB86590606Q35915704-CC4FE4D7-7307-4350-8C38-471E4D4B55AEQ35968436-A6E7ED99-1A3A-47EE-9FBE-D0D93192FA41Q36085709-DD18632B-3FE3-4620-976C-A1DCE0D77072Q36171820-7B8515EA-AC5B-41CB-A016-DF9D5981F572Q36230845-66D49D62-A2F3-4A09-A689-1C322B5FC4EEQ36348346-EAEE9151-21FC-4654-8106-553BA7E672C7Q37066228-F55D4A17-DEB0-4D65-B397-A70AE22ECE75Q38874623-28352B35-89B2-4E1B-9D8D-8E5B5E2DEF35Q39506153-3A3CB5D3-5326-4E8C-B520-7DA881DCB595Q39860625-FD7355A6-C244-40CB-8252-6C320094BD5AQ40212331-3B8965D8-59CB-480D-9915-B26A43231E94Q41982319-7CC8E5A7-F696-4369-97CD-C68BF3CAB90DQ42252699-D1E27180-9F40-474E-9ACC-672E99241D4BQ44819846-4CFBF9D6-B25D-4BBF-ABE4-4EC0C790102DQ45721911-ED48CF21-7890-4D12-A731-563B94C3282EQ45871503-1190DAA0-9501-467E-9A5B-E63323BB4F97Q45874307-23369956-658C-4F0A-BF14-8A63C9F465AB
P2860
Persistent expression of canine factor IX in hemophilia B canines.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Persistent expression of canine factor IX in hemophilia B canines.
@en
Persistent expression of canine factor IX in hemophilia B canines.
@nl
type
label
Persistent expression of canine factor IX in hemophilia B canines.
@en
Persistent expression of canine factor IX in hemophilia B canines.
@nl
prefLabel
Persistent expression of canine factor IX in hemophilia B canines.
@en
Persistent expression of canine factor IX in hemophilia B canines.
@nl
P2093
P2860
P921
P356
P1433
P1476
Persistent expression of canine factor IX in hemophilia B canines.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3301024
P577
1999-10-01T00:00:00Z
P5875
P6179
1008888203